Jimeno Cecilia, Anonuevo-Cruz Ma Cecille, Uy Angelique Bea, Bacena Adrian Oscar, Francisco Mark David, Tiglao-Gica Angelique Love, Bruno Racquel, Corpuz Diane Grace
Division of Endocrinology, Diabetes and Metabolism, University of the Philippines-Philippine General Hospital.
J ASEAN Fed Endocr Soc. 2020;35(1):14-25. doi: 10.15605/jafes.035.01.05. Epub 2020 May 16.
Diabetes mellitus (DM) is a known risk factor for morbidity and mortality among patients with COVID-19 based on recent studies. While there are many local and international guidelines on inpatient management of diabetes, the complicated pathology of the virus, the use of glucose-elevating drugs such as glucocorticoids, antivirals and even inotropes, and various other unique problems has made the management of in-hospital hyperglycemia among patients with COVID-19 much more difficult than in other infections. The objective of this guidance is to collate and integrate the best available evidence that has been published regarding in-patient management of diabetes among patients with COVID-19. A comprehensive review of literature was done and recommendations have been made through a consensus of expert endocrinologists from the University of the Philippines-Philippine General Hospital (UP-PGH) Division of Endocrinology, Diabetes and Metabolism. These recommendations are evolving as we continue to understand the pathology of the disease and how persons with diabetes are affected by this virus.
根据最近的研究，糖尿病（DM）是2019冠状病毒病（COVID-19）患者发病和死亡的已知风险因素。虽然有许多关于糖尿病住院管理的本地和国际指南，但该病毒复杂的病理、糖皮质激素、抗病毒药物甚至血管活性药物等升糖药物的使用，以及各种其他独特问题，使得COVID-19患者的院内高血糖管理比其他感染要困难得多。本指南的目的是整理和整合已发表的关于COVID-19患者糖尿病住院管理的最佳现有证据。我们进行了全面的文献综述，并通过菲律宾大学菲律宾总医院（UP-PGH）内分泌、糖尿病和代谢科的专家内分泌学家达成共识提出了建议。随着我们对该疾病病理以及糖尿病患者如何受这种病毒影响的不断了解，这些建议也在不断演变。
